Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Revvity Inc (RVTY) Price & Performance

MasterCard IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Revvity Inc — how do they compare? MasterCard Inc trades at $558.53 (market cap $491.83B), while Revvity Inc trades at $115.77 (market cap $12.91B). The key difference: MasterCard Inc is far larger — about 38.1× Revvity Inc's market cap, and MasterCard Inc pays the higher dividend (0.62%). Which is the better fit depends on your goals.

MARVTY
Market Cap
$491.83B$12.91B
Volume
4,635,698
Sector
Consumer CyclicalTechnology
52-Week High
$598.96$117.75
52-Week Low
$471.55$82.26
Enterprise Value
$504.86B$15.23B
Dividend Yield
0.62%0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $557.09, down 1.08% today, but maintains strong bullish technical momentum with consistent earnings beats and robust financial performance. The company reported Q2 2026 EPS of $5.04, beating expectations of $4.77, continuing a pattern of strong quarterly results. Revenue growth remains solid with 2025 revenue reaching $32.79 billion and net income of $14.97 billion, demonstrating the company's dominant position in payment processing. Recent institutional buying activity and positive analyst sentiment support the stock's upward trajectory.

Mastercard presents a compelling investment opportunity with strong fundamentals, consistent earnings growth, and bullish analyst consensus. The stock offers 18.6% upside to the consensus price target of $660.85. Key risks include competitive threats from emerging payment technologies and potential regulatory challenges in the financial services sector. The company's aggressive AI investments and global expansion initiatives position it well for continued growth, though investors should monitor payment industry disruption from stablecoins and digital payment innovations.

Revvity Inc

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY